I recently had a chat with a new client who’d just switched to HDMZ after a frustrating run with a big-name public relations (PR) communications firm. During the meeting, they shared how relieved they were that our team actually grasped the science behind their technology platform. And not just the buzzwords, mind you, but the real mechanisms driving their data.
They told me the previous agency talked a good game about being “science-first,” but every deliverable and campaign idea came off as completely generic. Instead of moving things forward, the client ended up spending most of their time educating the team and reworking whatever came back, which resulted in way more babysitting than actual progress.
That conversation stuck with me. It wasn’t the first time I’d heard it, and it got me asking: In an industry as intricate as life sciences, how do you make sure your PR firm truly understands the science, and more importantly, knows how to turn it into narratives that move the needle?
Setting the stage in a crowded life science landscape
The life sciences PR world is more packed than ever. Agencies and firms of all sizes are vying for biotech, pharma, and medtech clients, and they all tout “deep scientific expertise” as a core strength. It’s become table stakes, or at least, that’s what they’d like you to believe.
But I’ve been hearing a different story from clients lately. Many are walking away disappointed from these so-called science-savvy firms.
It's about not only lacking the basics, but also failing to connect the dots in a field that's grown incredibly complex.
Sure, having a science degree is critical, but it doesn’t go far enough anymore. You need to grasp the nuances of the life sciences industry (e.g., drug development, diagnostics, tools and reagents, clinical research, service providers, etc.), the regulatory maze, funding dynamics, mergers and acquisitions trends, and even the business side of running a life sciences company.
And let’s not forget the audiences who need to be handled with care, including journalists who demand timeliness, venture capitalists scrutinizing every claim, patient advocates pushing for real impact, key opinion leaders (KOLs) expecting thoughtful dialogue, and physicians who need data they can trust.
The real problems when science takes a back seat
Hiring a PR firm without that strong scientific foundation is a recipe for headaches, and worse — missed opportunities. I’ve seen it play out too many times. For example:
- They struggle to dig up the compelling angles in your science story, leaving your announcements feeling flat and forgettable.
- Without context on industry trends, they can’t tie your work to the bigger picture, such as how your novel technology fits into the broader biotech/pharma landscape.
- Oversimplified explanations or an over-reliance on artificial intelligence can lead to lost credibility, or even outright errors, that spark a PR crisis over inaccurate claims.
- Endless review cycles on deliverables — from press releases to white papers — because clients end up doing the heavy lifting to review and correct the science.
- Boring, cookie-cutter strategies that revolve around milestone press releases without highlighting the innovation, nuance, or thought leadership that sets you apart.
- Worst of all, PR reps who can’t hold their own in conversations with critical stakeholders, including journalists probing for details, staff scientists developing flagship technologies, investors grilling on data implications, or partners evaluating synergies. (If your PR firm is meant to be a core representative of your brand, fumbling those interactions is a massive disservice.)
And in a sector in which precision matters as much as progress, these gaps can derail precious momentum.
After many years in this space, I’ve come to believe that your PR agency should feel like an extension of your team — frontline ambassadors who not only nail the communications basics, but also amplify your story through genuine scientific insight. In today’s high-stakes life sciences arena, partnering with a boutique firm in which deep science and industry expertise are embedded in every strategy isn’t just nice to have. It’s a force multiplier for achieving your desired future state. It elevates your narrative, builds authentic connections with savvy audiences, and drives toward real milestones such as funding rounds, partnerships, and market breakthroughs.
At HDMZ, this notion is core to our philosophy. We blend evidence-based insights with creative storytelling to challenge the status quo and fuel your growth. But how do you spot this in action? Beyond the table-stakes skills such as corporate communications, media relations, content development, and crisis management, look for teams that can:
- Hold competent, jargon-free conversations with journalists, because they’re out there not only representing your company and/or institution, but also proactively building relationships.
- Track trends not just in your vertical (e.g., gene editing, next-generation sequencing, immunology, RNA, etc.) but across the industry and media landscape, in an effort to tie your story to what your target audience actually cares about.
- Accurately interpret and contextualize complex data readouts from clinical trials or preclinical studies, ensuring press materials and executive commentary reflect the true statistical and clinical significance.
- Translate peer-reviewed publications into compelling, compliant narratives that highlight mechanistic insights, novelty, and implications without violating embargo rules or overstating findings. This also includes turning dense manuscripts into investor- and media-ready stories that stand up to scrutiny.
- Anticipate and address scientific misconceptions or criticisms in real time — whether from journalists, patient advocates, or social media — by drawing on deep domain knowledge to provide clear, evidence-based clarifications that build trust rather than defensiveness.
- Collaborate effectively with internal R&D and medical affairs teams to shape messaging around mechanisms of action, biomarker strategies, or competitive landscapes, which results in more authentic and defensible communications that resonate with key opinion leaders and regulators.
And these points are just the tip of the iceberg.
In essence, life sciences PR isn’t about generic announcements, as many firms tend to do today. It’s about strategic narrative-building around peer-reviewed publications, product launches, data readouts, and investor communications that demand scientific rigor.
A bench background can make a difference
As a former molecular biologist who’s spent time at the bench and published research, I’ve come to realize that it’s an invaluable edge in life sciences PR. It lets you spot the “devil in the details,” or those subtle scientific nuances that turn a good story into a standout one.
Take my own path, for instance. I majored in molecular and cellular biology as an undergrad, then pursued a master’s in medicine. I logged serious hours in the lab (under very trying conditions in South Korea), diving into calcium signaling’s role in immunology, sperm motility, muscle function, and purifying novel enzymes for commercial use. That hands-on experience taught me how to interrogate data, question assumptions, and communicate complex ideas without losing the essence. It’s why, at HDMZ, we prioritize teams with science degrees, former researchers, and industry vets who live and breathe this world.
Does a science background guarantee results? Of course not, because PR is as much art as science. But it stacks the odds heavily in your favor and acts as that force multiplier by uncovering angles generalists miss and streamlining everything from strategy to execution.
Real-world examples of science-first PR in action
To make this concrete, consider a few examples from science-driven PR campaigns our team has led, which have been genericized to maintain client confidentiality.
For one biopharma client with a novel antibody for cancer, we didn’t just blast a press release on their Phase I data readout. Drawing on our team’s immunology expertise, we prioritized value creation over time by differentiating its unique mechanism of action and contextualizing it against emerging trends in checkpoint inhibitors. This resulted in landing key media features and securing large pharma introductions that eventually helped close a multi-billion dollar acquisition, all for a single drug asset.
Another leading manufacturer of molecular biology reagents was developing a fascinating point-of-care diagnostic platform that not only addressed key limitations of traditional polymerase chain reaction (PCR)-based testing, but also delivered results at a fraction of the cost, without electricity or cumbersome, expensive equipment. Our deep knowledge of PCR mechanics and alternative isothermal amplification methods enabled us to craft compelling thought leadership op-eds for key outlets. These pieces positioned the company as a true innovator in accessible molecular diagnostics, thereby igniting interest from potential collaborators. The effort sparked numerous partnership inquiries, and our client continues to receive them to this day.
And finally, for a gene editing company announcing the initiation of a first-in-human clinical trial using a novel gene editing approach for a rare disease, our team’s deep expertise in genomics, gene editing mechanics, delivery vectors, and rare disease biology enabled us to craft precise, compelling narratives. These highlighted the strategy’s key differentiators — such as enhanced specificity, reduced off-target risks, or improved editing efficiency — while accurately framing the trial’s potential impact. This resulted in widespread mainstream media coverage that amplified the story beyond trade publications, ultimately paving the way for strategic partnerships with several leading large pharma companies.
What’s important here is that these cases aren’t just random wins or lucky breaks. They’re exactly what can happen when you build everything around a science-first ethos that turns solid communications work into real drivers for growth, new partnerships, and the kind of credibility that sticks around.
Closing thoughts
This all circles back to that client anecdote I shared at the start. In life sciences, in which everything is high-stakes and insanely complex, PR that just skims the surface isn’t going to move the needle. You need partners who truly understand the science, who can take dense data and complicated mechanisms and shape them into stories that actually land with partners, investors, KOLs, or whoever needs to hear it.
And one final thought. Having a PR team that’s genuinely science-savvy makes a huge difference in building media relationships, too. In fact, I still remember receiving the following email from a Wall Street Journal reporter I work with:
“Hey, thank you for giving me the idea for this story. It’s great to talk to someone who’s an actual scientist and knows what he’s talking about!”
That kind of trust doesn’t happen by accident.
